Ipsen
Ipsen is a French pharmaceutical company headquartered in Paris, France.[self-published source] It is specialized in oncology, neuroscience and rare diseases. It is publicly traded on the Euronext Paris as part of the SBF 120 index (2005).
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Cabometyx | Cabozantinib | 2016-09-09 | 2024-2033 | |
| Cometriq | Cabozantinib | 2014-03-21 | 2024-2033 | |
| Dysport | Abobotulinumtoxina | 2009-04-29 | ||
| Increlex | Mecasermin | 2005-08-30 | ||
| Nutropinaq | Somatropin | 2001-02-15 | ||
| Onivyde | Irinotecan | 2015-10-22 | 2025-2036 | |
| Somatuline depot | Lanreotide | 2007-08-30 | ||
| Sohonos | Palovarotene | 2023-08-16 | 2031-2037 | |
| Bylvay | Odevixibat | 2021-07-20 | 2031-2041 |
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Indication |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use